Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.56 |
| ▸ | FLT3 | P36888 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786332 | 0.80 | IDO1 (0.60) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL6923977 | 0.79 | IDO1 (0.68) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL31342976 | 0.79 | IDO1 (0.49) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL29008283 | 0.78 | FLT3 (0.53) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL30148164 | 0.78 | IDO1 (0.66) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL7844858 | 0.78 | IDO1 (0.66) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL17958877 | 0.77 | FLT3 (0.51) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL9788957 | 0.74 | IDO1 (0.66) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL2730199 | 0.74 | IDO1 (0.66) | IDO1FLT3KDM4EMAPTDAO | |
| SCHEMBL9098845 | 0.74 | IDO1 (0.66) | IDO1FLT3KDM4EMAPTDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988680-B2 | Non-natural nucleosides as theranostic agents | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9029345-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-8981078-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2825546-A2 | NON-NATURAL NUCLEOSIDES AS THERANOSTIC AGENTS | Case Western Reserve University (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140329236-A1 | NON-NATURAL NUCLEOSIDES AS THERANOSTIC AGENTS | CASE WESTERN RESERVE UNIVERSITY | 2014-11-06 | — | — | US | disclosed |
| WO-2013033705-A2 | NON-NATURAL NUCLEOSIDES AS THERANOSTIC AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130004945-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114847-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100111839-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J | 2010-05-06 | — | — | US | disclosed |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY | 2009-02-19 | — | — | US | disclosed |
| WO-2008147454-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2006101911-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329236-A1 | NON-NATURAL NUCLEOSIDES AS THERANOSTIC AGENTS | TYMP, TYMS, UNG | IDO1 2314/4885FLT3 1329/4885KDM4E 4106/4885 |
| US-20100111839-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | RPA1, RPA3, PCNA | IDO1 4346/4885FLT3 3025/4885KDM4E 3663/4885 |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | REV1, PCNA, DNA2 | IDO1 2964/4885FLT3 3081/4885KDM4E 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.